Ilex Clolar Efficacy Plus Transplant Success Is Likely Focus For Cmte. Review
This article was originally published in The Pink Sheet Daily
Executive Summary
One important issue will be the percentage of patients who have a successful transplant after responding to Clolar, briefing documents state. For patients who do not have a transplant, success depends on response duration, survival, toxicity and results achievable with other therapy. Study size is also likely topic for the committee.
You may also be interested in...
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.
Marqibo Advisory Committee Review Will Consider Benefit Of Partial Response
FDA's Oncologic Drugs Advisory Committee will consider whether partial responses are likely to predict clinical benefit of Inex/Enzon's liposomal vincristine injection for non-Hodgkin's lymphoma at its Dec. 1 meeting. The committee will also consider Marqibo's benefit over existing therapies.